Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives

Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treatment of patients with relapsed and refractory hematologic malignancies and is increasingly investigated as therapeutic option of other malignancies. The main adverse effect of CAR T-cell therapy is potentially life-th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Am Coll Cardiol
Main Authors: Ganatra, Sarju, Carver, Joseph R., Hayek, Salim S., Ky, Bonnie, Leja, Monika J., Lenihan, Daniel J., Lenneman, Carrie, Mousavi, Negaresh, Park, Jae H., Perales, Miguel Angel, Ryan, Thomas D., Scherrer-Crosbie, Marriele, Steingart, Richard M., Yang, Eric H., Zaha, Vlad, Barac, Ana, Liu, Jennifer E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8211027/
https://ncbi.nlm.nih.gov/pubmed/31856973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacc.2019.10.049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados